Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II enzymes, which perform conjugation reactions. These enzymatic processes not only influence the pharmacokinetics of drugs but also determine therapeutic efficacy and the likelihood of adverse effects.
Genetic polymorphisms significantly affect both Phase I and Phase II drug-metabolizing enzymes. Variants in genes encoding these enzymes can alter their expression or function, leading to substantial variability in individual drug metabolism rates. For example, certain polymorphisms can result in ultra-rapid, extensive, intermediate, or poor metabolizer phenotypes, each with distinct clinical implications for drug dosing and safety.
Pharmacogenetic profiling enables healthcare providers to predict individual responses to specific drugs, facilitating personalized medicine approaches. CYP2C9 and VKORC1 polymorphisms together explain a significant portion of warfarin dose variability, with VKORC1 often accounting for a larger share (~15–30%) and CYP2C9 contributing ~5–10%, depending on the population. Environmental factors, such as diet and concurrent medications, also play substantial roles. These overlapping influences complicate the translation of genotypic data into precise clinical dosing.
Currently, pharmacogenetic labeling is available for over a hundred FDA-approved drugs. However, clinical implementation remains limited by the need for more robust validation studies and standardized guidelines. Advances in this field will depend on continued research into gene-drug interactions and the integration of genetic data into electronic health records to support evidence-based, individualized therapeutic strategies.
Drug metabolism chemically modifies drugs and xenobiotics to increase polarity and aid elimination.
This process is mediated by Phase I enzymes through oxidation, reduction, and hydrolysis, and by Phase II enzymes via conjugation reactions.
Genetic polymorphisms in these enzymes can significantly alter drug metabolism, causing inter-individual variability in drug response.
Pharmacogenetic profiling helps to predict individual drug responses, enabling personalized dosing to reduce side effects or treatment failure.
However, translating enzyme data into clinical decisions is challenging due to the influence of numerous factors, such as age, weight, and diet.
For instance, the variability in warfarin therapy highlights the influence of genetic factors like CYP2C9 and VKORC1, along with environmental conditions, on differences in individual drug responses.
Over seventy approved drugs currently include pharmacogenetic guidance in their labeling. These recommendations help inform prescribing decisions, but more robust clinical studies are needed to validate and integrate this data into routine practice.
繁體中文
